SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Palantir Technologies, Inc. engages in the business of building and deploying software platforms that serve as the central operating systems for its customers. It operates through the Commercial and Government segments. The Commercial segment focuses on customers working in non-government industries. The Government segment is involved in providing services to customers that are the United States government and non-United States government agencies. Its platforms are widely used in areas such as defense, intelligence, healthcare, energy, and financial services, supporting data integration, large-scale analytics, and operational decision-making. The company was founded by Alexander Ceadmon Karp, Peter Andreas Thiel, Stephen Cohen, Joseph Lonsdale, and Nathan Dale Gettings in 2003 and is headquartered in Denver, CO.

Palantir Technologies Inc - Ordinary Shares - Class A

Palantir Technologies Inc

Palantir is trending as a report surfaced regarding security flaws in a battlefield communication system, triggering a sharp sell-off despite the company's rebuttal and claims that the issues were resolved. The community is debating the severity and validity of the report, with some viewing it as a buying opportunity while others express concerns about the company's valuation. Discussions also involve the potential impact on government contracts and the trustworthiness of news sources.

Hims & Hers Health, Inc. operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.

Hims & Hers Health Inc - Ordinary Shares - Class A

Hims & Hers Health Inc

Hims & Hers Health is trending amid discussions around Novo Nordisk's potential entry into the telehealth space with an obesity pill, which could impact HIMS' market share, while others are pointing out that weightloss is only a small part of the business. The community is debating whether this news presents a buying opportunity or signals a concerning shift in the competitive landscape, especially since some are looking at the COO exit as a negative catalyst. Some traders are noting technical levels and expressing frustration with the stock's volatile price action and seeming sensitivity to news.

Luckin Coffee, Inc. engages in providing food and beverage items, and operates coffee retail stores. It has a pioneered a technology-driven retail network to provide coffee and other products of high quality, high convenience and high affordability to customers. The company manages pick-up stores, relax stores, and delivery kitchens. It also offers tea, snacks, and light meals through its mobile application. The company was founded by Zhi Ya Qian, Fei Yang and Jin Yi Guo on June 16, 2017 and is headquartered in Xiamen, China.

Luckin Coffee Inc - ADR

Luckin Coffee is trending as investors discuss its potential U.S. expansion and speculate on a possible Nasdaq relisting, with community members pointing to strong fundamentals driving the stock. The company's growth in China, coupled with Starbucks' struggles, is fueling optimism, while others remain cautious due to past accounting issues and the stock's OTC status.

Rigetti Computing, Inc. provides full-stack quantum computing services. It serves global enterprise, government, and research clients through its Rigetti Quantum Cloud Services platform. The company was founded by Chad Rigetti in 2013 and is headquartered in Berkeley, CA.

Rigetti Computing Inc

RGTI is trending as retail investors and traders discuss its impressive recent gains and potential for future growth within the quantum computing sector. Community members are weighing the possibility of a short squeeze against concerns of overvaluation and a potential offering, while some highlight a recent purchase order announcement. The stock's momentum is drawing attention, with debates swirling around its long-term prospects compared to others in the quantum computing space.

Archer Aviation, Inc. engages in the development of electric vertical take-off and landing (eVTOL) aircraft. The company was founded by Brett Adcock and Adam Goldstein on October 16, 2018, and is headquartered in San Jose, CA.

Archer Aviation Inc - Ordinary Shares - Class A

Archer Aviation Inc

Archer Aviation ($ACHR) is trending amid high trading volume and anticipation surrounding potential catalysts, including upcoming airshows and FAA certification progress. The community is actively discussing the possibility of a short squeeze, as well as potential partnerships, with some drawing attention to Tesla's presence in a recent promotional video. Discussions also involve comparisons to sector peer Joby Aviation, with some traders anticipating $ACHR closing the market cap gap.

Meta Platforms, Inc. engages in the development of social media applications. It builds technology that helps people connect and share, find communities, and grow businesses. It operates through the Family of Apps (FoA) and Reality Labs (RL) segments. The FoA segment consists of Facebook, Instagram, Messenger, WhatsApp, and other services. The RL segment includes augmented, mixed and virtual reality related consumer hardware, software, and content. The company was founded by Mark Elliot Zuckerberg, Dustin Moskovitz, Chris R. Hughes, Andrew McCollum, and Eduardo P. Saverin on February 4, 2004, and is headquartered in Menlo Park, CA.

Meta Platforms Inc - Ordinary Shares - Class A

Meta Platforms Inc

META is trending as investors debate its AI spending and monetization strategies, highlighted by a recent report on AI chatbots exploring ad revenue. Community chatter reflects concerns about its recent price action, with some viewing it as a buying opportunity while others express bearish sentiment. Broader discussions include Meta's competition in the AI and AR spaces, particularly around its smart glasses.

USA Rare Earth, Inc. is domestic supplier of rare earth magnets and heavy rare earth elements. It is developing a vertically integrated, domestic supply chain for rare earth element magnet production, with a facility in Stillwater, Oklahoma, and mining rights to the Round Top heavy rare earth and critical minerals deposit in West Texas. The company was founded in May 2019 and is headquartered in Stillwater, OK.

USA Rare Earth Inc. - Ordinary Shares - Class A

USA Rare Earth Inc

USA Rare Earth (USAR) is trending due to speculation surrounding potential US government investment, fueled by the CEO's confirmation of White House discussions; the community is debating the significance of these talks and comparing USAR to other rare earth companies like MP Materials and LAC. Some investors are concerned about potential dilution from share unlocks and insider selling, while others remain optimistic about USAR's role in securing a domestic rare earth supply chain amid increasing geopolitical tensions.

C3.ai, Inc. engages in the provision of enterprise artificial intelligence software for digital transformation. It delivers the C3 AI suite for developing, deploying, and operating large-scale AI, predictive analytics, and Internet of Things applications in addition to a portfolio of turn-key AI applications. It operates through the following geographical segments: North America, Europe, The Middle East, and Africa, Asia Pacific, and Rest of World. The company was founded by Thomas M. Siebel, Patricia A. House and Stephen Maurice Ward, Jr. on January 8, 2009 and is headquartered in Redwood City, CA.

C3.ai Inc - Ordinary Shares - Class A

C3.ai Inc

C3.ai is trending amid speculation of a potential buyout, with community members pointing to increased volume and options activity as possible indicators. Chatter suggests that a big tech company could be interested in acquiring the AI firm to bolster its own AI capabilities. Despite recent financial results and leadership changes, the stock is seeing increased interest.

Clene, Inc. is a clinical-stage biopharmaceutical company, which focuses on the discovery, development, and commercialization of novel clean-surfaced nanotechnology therapeutics. It offers a nanotechnology drug platform for the development of a new class of orally administered neurotherapeutic drugs. The company was founded in 2013 and is headquartered in Salt Lake City, UT.

Clene Inc

CLNN is trending as community members discuss the potential for accelerated approval of its ALS treatment following positive commentary from the FDA. Conversations revolve around the company's cash flow, potential offerings, and the possibility of a data leak driving the recent price movement. Some investors express excitement and relief, while others remain cautious due to past experiences and the need for further positive developments.

Alto Neuroscience, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of psychiatric drugs. Its pipeline is composed of five clinical-stage assets which initially target depressive disorder and schizophrenia population. The company was founded by Amit Etkin, Dan Segal, and Wei Wu on March 25, 2019 and is headquartered in Mountain View, CA.

Alto Neuroscience Inc.

Alto Neuroscience is trending amid community discussion around a potential short squeeze and recent gains. Some traders cite the company's fundamentals, upcoming data readouts, and potential for a large upside. Others remain cautious, pointing to past trial failures and ongoing discussions about a possible offering.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

BIIB's sNDA for Higher Dose of SMA Drug Spinraza Gets FDA's CRL

FDA issues CRL to Biogen's regulatory filing seeking approval for a higher dose of SMA drug, Spinraza. The company plans prompt resubmission.

IONS' Rare Neurological Disease Drug Meets Late-Stage Study Goal

Ionis' zilganersen hits its phase III goal in Alexander disease, paving the way for a potential FDA filing in early 2026.

Several firms increased their price target on Ionis Pharmaceuticals (IONS) on Tuesday after the company announced positive results from a study of its Zilganersen drug in children and adults living with a rare neurological condition called Alexander disease (AxD).The company <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://ir.ionis.com/news-releases/news-release-details/ionis-announces-positive-topline-results-pivotal-study">announced</a> on Tuesday that in the study, Zilganersen 50 mg demonstrated statistically significant and clinically meaningful stabilization of the primary endpoint, gait speed, at week 61 compared to the control arm, with a favorable safety and tolerability profile. The company also said that Zilganersen indicated evidence of slowed disease progression, stabilization, or improvement.The firm intends to submit a new drug application to the U.S. Food and Drug Administration in the first quarter (Q1) of 2026. According to Ionis, Alexander Disease affects approximately one in one to three million people worldwide and has no approved disease-modifying treatments. The disease is characterized by progressive neurological deterioration, resulting in loss of functional mobility, independence, and the inability to control muscles for large movements, swallowing, and airway protection.Guggenheim on Tuesday raised its price target on the stock to $92 from $90, while maintaining a ‘Buy’ rating on the shares, according to TheFly. The new price target implies an upside of about 50% from the stock’s closing price on Monday.Other firms also hiked their price targets:<ol><li>Bank of America hiked its price target on IONS to $83 from $81 with a ‘Buy’ rating, while terming the news “an incremental positive” as Ionis could add another product to its expanding commercial portfolio.&nbsp;</li><li>Morgan Stanley hiked its price target on IONS to $86 from $71 while keeping an ‘Overweight’ rating on the shares.</li><li>Barclays also raised its price target on IONS to $80 from $78, with an ‘Overweight’ rating. The study results create a high probability of FDA approval, the analyst said.</li></ol>On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/IONS">IONS stock</a> stayed within the ‘bearish’ territory over the past 24 hours, while message volume rose from ‘extremely low’ to ‘low’ levels. Shares of the company traded over 2% higher at the time of writing.<figure class="image"><img style="aspect-ratio:574/63;" src="https://news.stocktwits-cdn.com/Screenshot_2025_09_23_at_11_39_52_AM_png_6ae39ea7d7.webp" alt="IONS' Sentiment Meter and Message Volume as of 11:40 a.m. ET on Sept. 23, 2025 | Source: Stocktwits" width="574" height="63"><figcaption>IONS' Sentiment Meter and Message Volume as of 11:40 a.m. ET on Sept. 23, 2025 | Source: Stocktwits</figcaption></figure>IONS' stock is up 80% this year and approximately 50% over the past 12 months.&nbsp;Read also:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/us-regulator-closes-probe-into-ford-bronco-vehicles-after-recent-recall/chDhCRLR35q">US Regulator Closes Probe Into Ford Bronco Vehicles – Here’s What Happened</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the Ionis Pharmaceuticals logo is seen displayed on a smartphone screen. (Photo Illustration by Thomas Fuller/SOPA Images/LightRocket via Getty Images)

Ionis Pharma Stock Rises After Multiple Price Target Hikes On Heels Of Positive Study Results In Alexander Disease

Guggenheim on Tuesday hiked the price target on the stock to $92 from $90 while keeping a ‘Buy’ rating on the shares. 

Equity

Guggenheim on Tuesday hiked the price target on the stock to $92 from $90 while keeping a ‘Buy’ rating on the shares. 


IONS Up on FDA's Breakthrough Tag for ION582 in Angelman Syndrome

Ionis jumps as FDA grants Breakthrough Therapy status to ION582 for treating Angelman syndrome, with the phase III study now underway.

IONS Hits 52-Week High on Tryngolza's Success in Lowering Triglyceride

Ionis surges to a 52-week high after Tryngolza shows strong triglyceride reductions and cuts acute pancreatitis risk by 85% in late-stage studies.

Ionis Pharmaceuticals, Inc. (IONS) announced on Tuesday that its medicine, Olezarsen, reduced triglycerides and acute pancreatitis events in late-stage trials evaluating the drug in individuals with severe hypertriglyceridemia.Severe hypertriglyceridemia (sHTG) is defined by severely high triglycerides reaching into the thousands. It is characterized by an increased risk of acute pancreatitis and other morbidities. According to Ionis, approximately three million people are living with sHTG in the U.S., including more than one million who are considered high risk.In two <a target="_blank" rel="noopener noreferrer nofollow" href="https://ir.ionis.com/news-releases/news-release-details/olezarsen-significantly-reduces-triglycerides-and-acute">studies</a>, Olezarsen demonstrated a highly statistically significant placebo-adjusted mean reduction in fasting triglycerides of up to 72% at six months, as well as a highly statistically significant 85% reduction in acute pancreatitis events, with favorable safety and tolerability profiles. The two trials cumulatively enrolled nearly 1,100 patients who were required to be on standard-of-care lipid-lowering therapy throughout the treatment period.<a href="https://stocktwits.com/symbol/IONS">IONS stock</a> rocketed by 34% by Tuesday afternoon, reaching its February 2021 highs. On Stocktwits, retail sentiment around IONS jumped from ‘bearish’ to ‘extremely bullish’ over the past 24 hours, while message volume rose from ‘low’ to ‘extremely high’ levels.<figure class="image"><img style="aspect-ratio:624/59;" src="https://news.stocktwits-cdn.com/Screenshot_2025_09_02_at_2_02_09_PM_png_166853294f.webp" alt="IONS's Sentiment Meter and Message Volume as of 2:02 p.m. ET on Sept. 2, 2025 | Source: Stocktwits" width="624" height="59"><figcaption>IONS's Sentiment Meter and Message Volume as of 2:02 p.m. ET on Sept. 2, 2025 | Source: Stocktwits</figcaption></figure>A Stocktwits user expressed optimism about the company’s future.<stembedurl>https://stocktwits.com/Mookins/message/627214651</stembedurl>Sam Tsimikas, senior vice president of global cardiovascular development at Ionis, termed the data “groundbreaking” and noted that the data reinforce the company’s confidence that the medicine has the potential to change how sHTG is treated. According to the firm, current standard of care therapies for sHTG and lifestyle modifications do not sufficiently or consistently lower triglyceride levels or reduce the risks of sHTG in all patients.Ionis plans to submit a supplemental new drug application (sNDA) to the U.S. Food and Drug Administration for approval of Olezarsen in sHTG by the end of the year. The drug is already approved in the U.S. as Tryngolza as an adjunct to diet to reduce triglycerides in adults with familial chylomicronemia (FCS).Several analysts hiked their price target on the stock following the news:<ul style="list-style-type:square;"><li>H.C. Wainwright raised its price target to $95 from $70 while keeping a ‘Buy’ rating on the shares. The firm also hiked its forecast for global Olezarsen sales up to $4.2 billion from $3.2 billion.</li><li>Jefferies raised its price target to $96 from $83 and kept a ‘Buy’ rating on the shares. The firm increased its estimate of Olezarsen's peak sales to about $2.5 billion from $1.5 billion due to higher assumed penetration in sHTG.&nbsp;</li><li>Barclays raised its target to $78 from $58, while keeping an ‘Overweight’ rating on the shares.</li><li>Morgan Stanley raised its price target to $71 from $62 and kept an ‘Overweight’ rating on the shares.</li></ul>IONS' stock is up 64% this year and approximately 21% over the past 12 months.&nbsp;Read also: <a href="https://stocktwits.com/news-articles/markets/equity/nio-expects-sales-bump-for-remainder-of-year-after-new-models-bring-strong-demand/chv6z3WRdFg">Nio Expects Sales Bump For Remainder Of Year After New Models Bring In Strong Demand: Retail Sees Stock Hitting At Least $10 By Year-End</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

IONS Stock Soars 34% To Hit February 2021 Highs After Medicine Shows Positive Effect On Elevated Triglyceride Levels In Late-Stage Studies 

In two studies, Ionis’ Olezarsen demonstrated a highly statistically significant placebo-adjusted mean reduction in fasting triglycerides of up to 72% at six months. 

Wall Street analysts boosted their targets on Ionis Pharmaceuticals after the FDA approved its RNA-based drug Dawnzera for hereditary angioedema, sparking a surge in retail chatter.&nbsp;BofA Securities raised its price target to $64 from $63 while maintaining a ‘Buy’ rating, saying Dawnzera’s approval was on time with a clean label that allows dosing every four or eight weeks and carries no major safety warnings, as per The Fly.Analyst Jason Gerberry said the firm’s decision to un-risk-adjust Dawnzera forecasts in its model supported the upward revision.Stifel also lifted its target to $43 from $38 but kept a ‘Hold’ rating, calling the approval “clean” and in line with other HAE labels.&nbsp;The firm said Ionis management is confident patients will continue switching from existing options due to unmet needs, describing Dawnzera as offering a compelling product profile.The FDA approval marked a milestone for Ionis, making Dawnzera the first and only RNA-targeted prophylactic treatment for HAE.&nbsp;The decision was based on results from the Phase 3 OASIS-HAE study, where the drug reduced monthly attack rates by 81% compared to placebo over 24 weeks. Longer-term data showed sustained reductions of more than 90% and strong patient preference in switch studies versus existing prophylactic therapies.HAE is a rare, potentially life-threatening condition marked by recurrent swelling attacks that affect about 7,000 people in the U.S.&nbsp;Dawnzera, which targets plasma prekallikrein, will be available in the U.S. in the coming days and can be self-administered via autoinjector once every four or eight weeks.Ionis CEO Brett Monia said the approval represents a “significant advance” for patients and marks the company’s second independent drug launch in nine months, following the approval of Tryngolza for familial chylomicronemia syndrome.On Stocktwits, retail sentiment for Ionis was ‘extremely bullish’ amid ‘extremely high’ message volume.One user said Ionis may not see much more upside from the FDA approval of Dawnzera, noting that “the next earnings will be the real mover” since the approval was already priced in.<stembedurl>https://stocktwits.com/moses_ametuer/message/626141804</stembedurl>Another user compared Ionis to other biotech names, pointing out they had a similar experience with Precigen and Tonix Pharmaceuticals last week. Both received FDA approvals but saw sharply different stock reactions, with Precigen rallying 75% after its trading halt while Tonix fell 15%.&nbsp;The trader added they were hoping for a good run with Ionis.<stembedurl>https://stocktwits.com/jvbiotek/message/626111256</stembedurl><a href="https://stocktwits.com/symbol/IONS">Ionis’ stock</a> has risen 23.7% so far in 2025.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Retail Traders Pile Into Ionis As Wall Street Hikes Price Targets On FDA Approval Of Swelling Disorder Therapy

BofA Securities raised its target to $64 with a ‘Buy’ rating, while Stifel lifted its target to $43 with a ‘Hold,’ both citing Dawnzera’s clean label and flexible dosing.

BioCryst Pharmaceuticals Before Q2 Earnings: How to Play the Stock

BCRX gears up for Q2 results with Orladeyo growth in focus, but 2025 EPS forecasts dip as investors eye pipeline progress.

Here's What Key Metrics Tell Us About Ionis Pharmaceuticals (IONS) Q2 Earnings

While the top- and bottom-line numbers for Ionis Pharmaceuticals (IONS) give a sense of how the business performed in the quarter ended June 2025, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

Ionis Pharmaceuticals (IONS) Q2 Earnings and Revenues Beat Estimates

Ionis Pharmaceuticals (IONS) delivered earnings and revenue surprises of +218.52% and +66.96%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

Ionis Pharmaceuticals, Inc. engages in the development and commercialization of human therapeutic drugs using antisense technology. The company was founded by Stanley T. Crooke, David J. Ecker, Christopher K. Mirabelli, and Brett P. Monia on January 10, 1989 and is headquartered in Carlsbad, CA.

Ionis Pharmaceuticals Inc

Will PepsiCo ($PEP) beat quarterly earnings? 
 
*Powered by Polymarket

Stocktwits

PepsiCo Inc

) beat quarterly earnings? 
 
*Powered by Polymarket

IONS
Ionis Pharmaceuticals Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest IONS News

IONS Ionis Pharmaceuticals Inc